Pemvidutide
Also known as: ALT-801, GLP-1/glucagon dual agonist
limited human dataNot FDA approvedResearch only
Published Dose Range
Low1.2 mg/week
Typical1.8-2.4 mg/week
High2.4 mg/week
Phase 2 MOMENTUM (obesity) and IMPACT (MASH) trials used 1.2, 1.8, and 2.4 mg weekly. Phase 3 not yet initiated as of 2026.
Published Cycle Range
No published cycle data available.
Administration
Routessubcutaneous
FrequencyOnce weekly
Preferred timingSame day each week
Safety Profile
Contraindications
- • Personal or family history of medullary thyroid carcinoma (class label)
Common side effects
- • Nausea
- • Vomiting
- • Diarrhea
- • Decreased appetite
Serious risks
- • Pancreatitis risk (class effect)
- • Modest LDL increase observed in trials
Drug interactions
- • Insulin
- • Sulfonylureas
Requires monitoring
- • Blood glucose
- • Lipid panel
- • Heart rate
Pregnancy / breastfeeding
Avoid — limited human data
Common Misconceptions
- Designed for both obesity and MASH (NASH) — same molecule pursued in two indications
- LDL increase is mechanism-related and may attenuate over time, but warrants lipid monitoring
Next Steps
Sign in to calculate your dose, add this compound to your stack, and check for interactions with your current cabinet.